<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669991</url>
  </required_header>
  <id_info>
    <org_study_id>20181082</org_study_id>
    <nct_id>NCT03669991</nct_id>
  </id_info>
  <brief_title>Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary Syndrome</brief_title>
  <official_title>Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to optimized the dose-adjusted regimen of beta-blockers in patients with
      acute coronary syndrome by investigating therapeutic and curative results of target doses
      Beta-blockers using the dose-adjusted pathway of beta-blockers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>Within 1 year after surgery</time_frame>
    <description>MACCE were defined as a composite of all-cause death, myocardial infarction (MI), unplanned target vessel revascularization (TVR), stent thrombosis (ST) and stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting heart rate</measure>
    <time_frame>Within 1 year after surgery</time_frame>
    <description>The resting heart rate of the body is the number of contractions of the heart that occur in a single minute while the body is at complete rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (systolic &amp; diastolic)</measure>
    <time_frame>Within 1 year after surgery</time_frame>
    <description>Blood pressure (BP) is the pressure of circulating blood on the walls of blood vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>Within 1 year after surgery</time_frame>
    <description>Ejection fraction (EF) is the volumetric fraction of fluid (usually blood) ejected from a chamber (usually the heart) with each contraction (or heartbeat).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum norepinephrine</measure>
    <time_frame>Within 1 year after surgery</time_frame>
    <description>Norepinephrine is a neurotransmitter that is secreted in response to stress.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute coronary syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Patients diagnosed as acute coronary syndromes including acute ST-segment elevation
             myocardial infarction (STEMI) and non-ST-segment elevated acute coronary syndrome
             (NSTE-ACS)

          -  Patients or whose legal representatives signed written informed consent form

        Exclusion Criteria:

        Patients should been excluded if they meet any of the following exclusion criteria:

          -  Patients with contraindications to the application of beta blockers, including: 1)
             cardiogenic shock or heart failure (Killip grade &gt; II level);2) sick sinus syndrome;
             3) II degree atrioventricular block;4) unstable decompensation of cardiac failure
             (pulmonary edema, hypotension or low perfusion); 5) symptomatic hypotension or
             bradycardia (heart rate&lt;50 beats/min, blood pressure&lt;90/60mmHg); 6) contraindications
             to beta blockers or allergy to any ingredient of beta blocker; 7) active asthma should
             be treated by inhalation preparation treatment

          -  Pregnant or lactating women

          -  Patients without signed written informed consent

          -  Patients who was considered by the researcher inappropriate to participate in this
             study (for example, patients with a higher risk of cardiogenic shock, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Da Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Yang, MD</last_name>
    <phone>+86-10-88396173</phone>
    <email>13810727489@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kuo Zhang, MD</last_name>
    <phone>+86-18813019602</phone>
    <email>kzhang23@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Da Tang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Da Tang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

